Art Cabenuva LA denied as experimental or investigational by Humana?

Humana's specific coverage criteria for art cabenuva la are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Cabenuva (Long-Acting) as Experimental

An "experimental or investigational" denial means Humana's medical policy concluded that the evidence for Cabenuva does not yet meet their internal threshold for coverage as an established treatment. This categorization is incorrect as a matter of regulatory fact: Cabenuva received FDA approval for the treatment of HIV-1 in adults. FDA approval is the threshold most courts and external reviewers apply when assessing whether an experimental denial is justified. A denial that contradicts FDA-approved status is among the most frequently overturned denial types.

It is important to distinguish between experimental and simply being a newer drug. Humana may have a policy lag — their internal evidence-review cycle sometimes trails FDA action — or the policy may impose criteria beyond FDA approval. Either way, you can rebut this denial with documentary evidence.

## Your Federal Appeal Rights

• Internal appeal (ACA §2719 / ERISA §503): You are entitled to a full-and-fair internal review. Your denial letter must state the specific clinical rationale and policy basis. Request the complete file including all clinical-criteria documents Humana relied on.
• External review: An independent review organization (IRO) — not Humana — will evaluate whether the experimental determination is consistent with generally accepted medical practice. Federal law gives you approximately four months from the denial date to file for external review; confirm the exact window in your plan documents.
• Expedited review: Available when your condition requires urgent treatment; turnaround is typically 72 hours.

## What to Gather

1. FDA approval documentation: The FDA drug-approval letter and current prescribing label for Cabenuva, establishing non-experimental status. 2. DHHS HIV treatment guidelines: Current guidelines from DHHS or equivalent authoritative HIV body referencing long-acting injectable cabotegravir/rilpivirine as a recognized treatment option. 3. Peer-reviewed clinical support: Your prescriber can cite published literature; you do not need trial statistics in the appeal letter itself — cite the existence of published peer-reviewed data and the FDA-approval basis. 4. Prescriber letter: A letter from your HIV specialist specifically addressing Humana's experimental designation and rebutting it with reference to FDA approval and guideline recognition. 5. Humana's own policy: Obtain the exact version of the policy used to deny you. Compare its "experimental" definition against the FDA-approved label.

## Criteria-Mapping Structure

Create a side-by-side table: left column lists each element of Humana's experimental/investigational definition; right column documents how Cabenuva fails to meet that definition (e.g., FDA approval date, guideline recognition, peer-reviewed publications). Attach the FDA label as Exhibit A. This structured rebuttal gives an IRO reviewer everything needed to overturn the denial without relying on any unverified clinical claim.